What Management Said

Read the full Q2 2025 transcript ↗

We are actively executing on our launch strategy, and I will provide specific updates on our initial progress, the near-term demand trends, the process for scheduling patients onto treatment, and our momentum with payers. In parallel, we are on track to increase our manufacturing capacity to treat 10 patients per month in mid-2026. Our 25-day manufacturing process begins immediately after biopsy is received at our manufacturing facility and culminates in the patient's return to the QTC for treatment, which is when we recognize revenue. Throughout this journey, our Abeona Assist Patient Navigators are ready and committed to supporting patients and the centers dealing with the logistics of biopsy and return to the QTC for treatment.

We anticipate that the first ZEVASKYN patient treatment will occur in the third quarter of 2025, which will initiate revenue generation, leading to our projected company-wide profitability in early 2026. As a reminder, revenue recognition occurs when the patient receives ZEVASKYN, that is, upon surgical application. At this early stage in our launch, it is premature to provide revenue guidance. As we transition into a revenue-generating commercial company, we will move away from providing cash runway guidance given the complexities of estimating future revenues in the early launch phase.

In lieu of runway guidance, we plan to provide high-level forward cost guidance alongside regular updates on the commercialization in progress. In addition to the reclassification of select R&D expense to SG&A, the increase in SG&A reflects increased headcount and professional costs associated with the commercial launch of ZEVASKYN. Now, I want to turn to another partner pipeline program, AAV gene therapy UX111, which is being developed by Ultragenyx for Sanfilippo Syndrome Type A, or MPS3A. Next, I turn to another partner pipeline program, AAV gene therapy TSHA-102, which is being developed by Taysha Gene Therapies for the treatment of Rett syndrome.

What went well
  • The quarter's defining event was the April 2025 FDA approval of ZEVASKYN (prademagene zamikeracel), the first and only autologous cell-based gene therapy for adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB) - the biggest milestone in Abeona's history.
  • The launch started fast: two Qualified Treatment Centers (QTCs) were activated - Lurie Children's Hospital of Chicago and Lucile Packard Children's Hospital at Stanford - and roughly 50 patients had already been identified (a dozen-plus at the QTCs plus nearly three dozen from referring non-QTC physicians).
  • Market access came together quickly: 100% of prior-authorization requests were approved to date (some within 48 hours, including Medicaid), the largest U.S. commercial payer UnitedHealthcare agreed to cover ZEVASKYN to its FDA label with no additional restrictions, and Abeona signed a National Drug Rebate Agreement with CMS covering all 51 Medicaid programs and Puerto Rico.
  • The balance sheet was transformed by the sale of the rare pediatric disease Priority Review Voucher received on approval: cash, equivalents, short-term and restricted investments rose to $225.9 million at June 30, 2025 from $98.1 million at year-end 2024, giving more than two years of runway before any ZEVASKYN sales.
  • The PRV gain drove Q2 2025 net income of $108.8 million ($2.07 basic / $1.71 diluted EPS), versus $7.4 million a year earlier, and the company reiterated a path to company-wide profitability in early 2026 with a break-even of about three treated patients per month.
  • Manufacturing was tracking to plan: the first commercial patient biopsy was completed at Lurie, the 25-day manufacturing process was underway, and capacity was on track to reach 10 patients per month by mid-2026.
What went wrong
  • There was still no commercial revenue in the quarter - the first ZEVASKYN treatment (and first revenue) slipped to the third quarter of 2025, as revenue is recognized only when the product is surgically applied.
  • The patient journey remained long and logistically heavy - roughly three to four months from identification to treatment, including payer medical authorization (a week or more) and payer financial agreement (about four to six weeks) before biopsy.
  • SG&A jumped to $17.1 million from $8.6 million a year earlier on commercial-launch headcount and professional costs, and certain former R&D costs (engineering runs) were reclassified into SG&A after approval.
  • A partner setback: Ultragenyx received a Complete Response Letter on the UX111 (MPS IIIA) BLA that Abeona had out-licensed, requesting additional CMC information (Ultragenyx believes the observations are readily addressable).
  • Management declined to give revenue guidance or launch KPIs, citing the many compounding variables in an unprecedented one-time therapy launch, and moved away from providing cash-runway guidance.

Guidance Changes

MetricPeriodCurrent guidance
ZEVASKYN patients treatedFY2025Reiterated 10-14 patients treated in 2025
First commercial revenueQ3 2025First patient treatment (and first ZEVASKYN revenue) anticipated in Q3 2025
Company-wide profitabilityEarly 2026Projected company-wide profitability in early 2026; break-even at roughly three treated patients per month
Manufacturing capacityMid-2026On track to reach 10 patients per month by mid-2026 (built in increments of two)
Financial guidance approachOngoingWithdrawing cash-runway guidance; will provide high-level forward cost guidance plus commercialization updates; revenue guidance premature

Performance Breakdown

MetricYoYNote
Net income $108.8M vs $7.4M Driven by the gain on sale of the rare pediatric disease Priority Review Voucher received on ZEVASKYN approval.
Diluted EPS $1.71 vs -$0.26 PRV gain; Q2 2024 diluted was a loss.
R&D expense $5.9M vs $9.2M Costs capitalized into inventory and certain production/engineering-run costs reclassified to SG&A following ZEVASKYN approval.
SG&A expense $17.1M vs $8.6M Commercial-launch headcount and professional costs plus reclassification of select R&D to SG&A.
Cash and investments $225.9M vs $98.1M (YE2024) Net proceeds from the PRV sale; over two years of runway before ZEVASKYN sales.
Identified patients ~50 A dozen-plus at the two QTCs plus nearly three dozen immediate candidates identified by referring non-QTC physicians.

Earnings Call Themes & Trends

TopicPrevious mentionCurrent periodTrend
ZEVASKYN commercial launchPre-approvalApproved April 2025; two QTCs live, first biopsy done, first treatment/revenue expected Q3 2025; goal to treat 10-14 patients in 2025.—
Market access / payers-100% prior-auth approval to date; UnitedHealthcare covering to label; CMS NDRA across all 51 Medicaid programs plus Puerto Rico; roughly 60% of RDEB lives commercial, 30% Medicaid, remainder Medicare.—
Manufacturing scale-upClinical25-day process; capacity ramping in increments of two toward 10 patients per month by mid-2026; going from six to ten requires FDA sign-off but no anticipated inspection.—
Pipeline / partners-Beacon Therapeutics exercised an option to license the AAV204 capsid; Ultragenyx UX111 (MPS IIIA) received a CRL; Taysha's TSHA-102 (Rett) advancing to pivotal trials.—
International expansion-Early evaluation of EU and Japan; likely supply from the Cleveland facility for select markets rather than building foreign manufacturing (a three-to-four-year effort).—

Q&A Summary

Kristen Kluska (Cantor) asked how 'identified patients' are defined.
Management said these are physician-identified severe RDEB patients with large, never-healed wounds - the most clinically burdened patients the centers want to prioritize first - representing the tip of a larger pool.
Jefferies asked about center capacity and how many treatments a QTC needs before adopting ZEVASKYN routinely.
Management said most sites' first ZEVASKYN case will be a commercial patient (no dry run except prior trial sites like Stanford/UMass), but the chosen centers already have the multidisciplinary infrastructure and RDEB experience; treating one or two patients is expected to be enough to scale.
Ram Selvaraju (H.C. Wainwright) asked about payment mechanics and prior-authorization requirements.
Revenue is recognized only after the product is applied, whether procured directly or via specialty pharmacy; the hospital can reach payer agreement before ordering, minimizing risk. No payer pushback requiring prior use of other RDEB treatments has been seen.
Oppenheimer asked about prior-auth volumes and manufacturing-capacity risk.
Management declined to give precise prior-auth counts (a dynamic number) but said the process is shortening; the CTO said the clinical-to-commercial ramp is on track for 10 patients/month by mid-2026 with only routine agency discussions, no expected inspection.
Alliance Global Partners asked about launch expectations versus the competitor and EU plans.
Management said patient demand is the key strength and declined to set KPIs this early given the unprecedented therapy; EU/Japan are under early evaluation with a preference to supply from Cleveland for select markets.

More on Abeona Therapeutics Inc.

Company

Abeona Therapeutics Inc. overview
Facet

Financials
Transcript

Q2 2025 call
Reported 2025-08-14 · figures from the Abeona Therapeutics Inc. Q2 2025 earnings call.

See how VectorShift works for your firm

Request Demo